195 related articles for article (PubMed ID: 27799204)
1. Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.
Robarge JD; Metzger IF; Lu J; Thong N; Skaar TC; Desta Z; Bies RR
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799204
[TBL] [Abstract][Full Text] [Related]
2. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
[TBL] [Abstract][Full Text] [Related]
5. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Desta Z; Metzger IF; Thong N; Lu JB; Callaghan JT; Skaar TC; Flockhart DA; Galinsky RE
Antimicrob Agents Chemother; 2016 Nov; 60(11):6813-6822. PubMed ID: 27600044
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
[TBL] [Abstract][Full Text] [Related]
9. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
Mukonzo JK; Röshammar D; Waako P; Andersson M; Fukasawa T; Milani L; Svensson JO; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Br J Clin Pharmacol; 2009 Nov; 68(5):690-9. PubMed ID: 19916993
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
Ayuso P; Neary M; Chiong J; Owen A
J Antimicrob Chemother; 2019 Nov; 74(11):3281-3290. PubMed ID: 31369088
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.
Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z
Clin Transl Sci; 2019 Nov; 12(6):657-666. PubMed ID: 31339646
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M; Di Iulio J; Buclin T; Rotger M; Lubomirov R; Cavassini M; Fayet A; Décosterd LA; Eap CB; Biollaz J; Telenti A; Csajka C;
Clin Pharmacol Ther; 2009 May; 85(5):485-94. PubMed ID: 19225447
[TBL] [Abstract][Full Text] [Related]
13. Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults.
Meng XM; Li ZR; Zheng XY; Liu YX; Niu WJ; Qiu XY; Lu HZ
Eur J Pharm Sci; 2021 Dec; 167():105986. PubMed ID: 34474119
[TBL] [Abstract][Full Text] [Related]
14. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
Cabrera SE; Santos D; Valverde MP; Domínguez-Gil A; González F; Luna G; García MJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
[TBL] [Abstract][Full Text] [Related]
15. PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM; Lau JL; Alvarellos ML; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Jul; 25(7):363-76. PubMed ID: 25966836
[No Abstract] [Full Text] [Related]
16. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.
Zubiaur P; Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Mejía G; Martín-Vilchez S; Abad-Santos F
Pharmacogenomics J; 2020 Apr; 20(2):235-245. PubMed ID: 31628422
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
[TBL] [Abstract][Full Text] [Related]
19. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
[TBL] [Abstract][Full Text] [Related]
20. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.
Mukonzo JK; Nanzigu S; Rekić D; Waako P; Röshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Clin Pharmacokinet; 2011 Aug; 50(8):531-40. PubMed ID: 21740076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
